MacroGenics (MGNX) Upgraded by Zacks Investment Research to Buy

MacroGenics stock has undergone multiple analysts rating changes in the recent past.  MacroGenics Upgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of MacroGenics traded up $0.45 on Tuesday, reaching $21.19. 0 shares of the stock traded hands, compared to its average volume of 887428. Shares of MacroGenics were trading at $21.19 on Tuesday. The firm’s 50 day moving average is $22.65 and its 200 day moving average is $25.63.MacroGenics has a 12 month low of $20.38 and a 12 month high of $36.48. While on yearly highs and lows, MacroGenics’s today has traded high as $21.38 and has touched $20.38 on the downward trend. See More Analyst Rating at: RATING

MacroGenics Earnings and What to expect: 

MacroGenics last announced its earnings data on July 29th, 2021. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.38. The company earned $30.76 million during the quarter, compared to the consensus estimate of $35.55 million. MacroGenics has generated ($2.47) earnings per share over the last year (($2.20) diluted earnings per share). Earnings for MacroGenics are expected to grow in the coming year, from ($2.86) to ($2.41) per share. MacroGenics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for MacroGenics are expected to grow in the coming year, from ($2.86) to ($2.41) per share. The P/E ratio of MacroGenics is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of MacroGenics is -9.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. MacroGenics has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

MacroGenics (MGNX) Moving Average Technical Analysis

5 day Moving Average is $20.62 And 5 day price change is $1.13 (5.63%)  with average volume for 5 day average is 269,900. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $21.06 and 20 day price change is -$6.01 (-22.10%) and average 20 day moving volume is 872,130. 50 day moving average is $22.65  and 50 day price change is -$4.11 ( -16.25%)  and with average volume for 50 days is : 704,438. 200 day moving average is $25.63  and 200 day price change is -$3.11 (-12.80%)  and with average volume for 200 days is : 757,200.

Other owners latest trading in MacroGenics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 84,602 which equates to market value of $2.27M and appx 0.00% owners of MacroGenics
  • On 8/23/2021 shares held by Morgan Stanley were 207,082 which equates to market value of $5.56M and appx 0.00% owners of MacroGenics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 104,258 which equates to market value of $2.80M and appx 0.00% owners of MacroGenics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 93.67% for MacroGenics

See More Analyst Rating at: RATING